DDInter1276 DDInter1676
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nelfinavir {u} (Compound) resembles {v} (Compound) Mitiglinide
Nelfinavir {u} (Compound) resembles {v} (Compound) Indinavir
Nelfinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Nelfinavir {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Nelfinavir {u} (Compound) upregulates {v} (Gene) AARS
Nelfinavir {u} (Compound) downregulates {v} (Gene) RPIA
Nelfinavir {u} (Compound) causes {v} (Side Effect) Injury
Nelfinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin lispro
Nelfinavir (Compound) resembles Mitiglinide (Compound)
Nelfinavir (Compound) resembles Indinavir (Compound)
Nelfinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Nelfinavir (Compound) binds CYP3A7-CYP3A51P (Gene)
Nelfinavir (Compound) upregulates AARS (Gene)
Nelfinavir (Compound) downregulates RPIA (Gene)
Nelfinavir (Compound) causes Injury (Side Effect)
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro